KD therapy that targets tumour metabolism and represses the NF‐κB‐mediated hypoxic response may provide a low‐toxic, easy‐to‐implement method for glioma aimed at angiogenesis inhibition. This evidence concerns the gene NFKB1 and central nervous system cancer.